An interview with Professional in Residence Mike Holmes: Pioneering genome editing tools in gene therapy
April 06, 2021
Mike Holmes, PhD, is the Chief Scientific Officer at Ambys Medicines and is joining the QB3-Berkeley Professionals in Residence (PIR) program on April 16th and 23rd. He spoke with PhD student Diana Aguilar Gómez about his career from being a graduate student to industry and his pioneering work in genome editing techniques in gene therapy.